OPEN ACCESS Freely available online

Advances in Pediatric Research

Opinion Article

Current Innovations and Prospective Advancements of Nanomedicine in Pediatric Healthcare

Yong Qu*

Department of Chemistry of Medicinal Natural Products, Sichuan University, Chengdu, China

DESCRIPTION

Nanomedicine has emerged as a potential approach for the treatment and diagnosis of various diseases, offering significant advantages over conventional therapies. It not only addresses formulation challenges associated with new therapeutic agents but also enhances the efficacy of existing drugs. Nanomedicine offers several benefits, including increased drug payload capacity, enhanced stability, customized drug release profiles, improved bioavailability and targeted drug delivery. These features have made nanomedicine an appealing and versatile tool in modern medicine. Over the past few decades, significant research and regulatory efforts have been dedicated to advancing nanomedicine from laboratory research to clinical application. As a result, numerous nanotechnology-based formulations have successfully reached commercialization, demonstrating the potential of this field to revolutionize healthcare.

Despite the remarkable progress in nanomedicine for adults, its application in pediatric populations has advanced at a much slower pace. Treating diseases in children requires more than just adjusting adult drug doses based on body weight or surface area, as there are fundamental physiological differences between children and adults. These differences influence critical pharmacokinetic and pharmacodynamic parameters, such as drug Absorption, Distribution, Metabolism, Excretion and Transport (ADMET). The unique and dynamic physiology of children, particularly in neonates and infants, adds complexity to the development of pediatric-specific nanomedicine. Consequently, translating nanodrugs designed for adults to pediatric indications involves significant challenges, including the need to address age-specific variations in organ function, enzyme activity and drug transporter expression.

Recognizing these challenges, there is an increasing need to focus on the development of nanomedicines tailored specifically for pediatric use. This review highlights the key physiological differences between children and adults that impact drug disposition and response. For example, in neonates, the immature liver and kidneys result in altered drug metabolism and excretion, while the underdeveloped gastrointestinal tract can influence drug absorption. Additionally, the composition and structure of pediatric cell membranes, blood-brain barriers and plasma protein levels differ from those of adults, affecting drug distribution and efficacy. Understanding these physiological variations is essential for designing pediatric-friendly nanomedicines that are both safe and effective.

Pediatric diseases that could benefit from nanomedicine approaches are another critical area of focus. Certain conditions, such as cancers, infectious diseases, genetic disorders and respiratory illnesses, are particularly promising candidates for nanomedicine due to the need for precise and targeted therapies. For instance, pediatric oncology often requires highly potent drugs with minimal off-target effects, making targeted drug delivery systems such as liposomes and polymeric nanoparticles highly suitable. Similarly, infectious diseases, which are prevalent in children, could benefit from nanotechnology-based formulations that enhance drug bioavailability and stability, enabling more effective treatments with fewer side effects.

Several nanotechnology-based formulation strategies have already been developed and commercialized for pediatric use. These include liposomes, nanocrystals, polymeric nanoparticles and lipid nanoemulsions. Liposomes, for example, are spherical vesicles with a phospholipid bilayer that can encapsulate both hydrophilic and hydrophobic drugs, protecting them from degradation and improving their stability. Liposomal formulations have been used to treat pediatric cancers and fungal infections, offering reduced toxicity compared to conventional therapies. Nanocrystals, on the other hand, increase the solubility and bioavailability of poorly water-soluble drugs, making them an attractive option for pediatric formulations where oral administration is preferred. Polymeric nanoparticles, composed of biodegradable polymers, provide controlled drug release and targeted delivery, making them suitable for conditions requiring sustained therapeutic effects. Lipid nanoemulsions, widely used in parenteral nutrition and drug delivery, are another example of nanotechnology successfully adapted for pediatric applications.

Correspondence to: Yong Qu, Department of Chemistry of Medicinal Natural Products, Sichuan University, Chengdu, China, E-mail: qu@scu.edu.cn

Received: 18-Nov-2024, Manuscript No. LDAPR-24-36442; **Editor assigned:** 20-Nov-2024, PreQC No. LDAPR-24-36442 (PQ); **Reviewed:** 04-Dec-2024, QC No. LDAPR-24-36442; **Revised:** 11-Dec-2024, Manuscript No. LDAPR-24-36442 (R); **Published:** 19-Dec-2024, DOI: 10.35248/2385-4529.24.11.094

Citation: Qu Y (2024). Current Innovations and Prospective Advancements of Nanomedicine in Pediatric Healthcare. Adv Pediatr Res.11:094.

While these advancements are promising, the development and commercialization of pediatric nanomedicine face significant challenges. One major hurdle is the lack of sufficient clinical data on the safety and efficacy of nanomedicine in children. Conducting clinical trials in pediatric populations is inherently challenging due to ethical considerations, recruitment difficulties and the need for age-specific study designs. Additionally, the regulatory pathways for pediatric nanomedicine are often complex and less well-defined compared to those for adult formulations. Ensuring that nanomedicines meet the safety, quality and efficacy standards required for pediatric use necessitates collaboration between researchers, clinicians and regulatory agencies.

Another challenge lies in the manufacturing and scaling-up of pediatric nanomedicine. Producing nanomedicines with consistent quality and performance is technically demanding and scaling up these processes for commercialization requires significant investment in infrastructure and expertise. Furthermore, the cost of developing pediatric-specific nanomedicine can be prohibitively high, especially for rare or orphan diseases where the market size is limited.

CONCLUSION

In conclusion, nanomedicine represents a transformative approach to pediatric drug development, offering solutions to long-standing challenges in treating diseases in children. While significant progress has been made, much work remains to overcome the barriers to widespread adoption and commercialization of pediatric-specific nanomedicine. By addressing these challenges and leveraging the potential of nanotechnology, researchers and clinicians can improve the lives of children worldwide, providing them with safer, more effective and more targeted treatment options. Such as stimulus-responsive nanoparticles and multifunctional nanocarriers, hold great potential for addressing the unique challenges of pediatric drug delivery. Additionally, increased awareness of the unmet medical needs of children has led to growing interest and investment in pediatric research, change of opinion for the new therapeutic options.